All Categories

Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study

Anouk Pels, Wes Onland, Rolf M. F. Berger, Arno F. J. van Heijst, Enrico Lopriore, Irwin K. M. Reiss, Jacqueline Limpens, Sanne J. Gordijn, Wessel GanzevoortUniversity of Amsterdam and Emma Children’s Hospital. University of Groningen, University Medical Center Groningen and Beatrix Children’s Hospital. Radboud University Medical Center and Amalia Children’s Hospital. Leiden University Medical Center. Erasmus University Medical Center. Netherlands European Journal of PediatricsEur J Pediatr 2022; 181: 1709-1718DOI: 10.1007/s00431-021-04355-x AbstractThe aim was […]

Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study Read More »

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Christine M. Pierce, Min H. Zhang, Baldvin Jonsson, Dinu Iorga, Narayan Cheruvu, Cecile C. Balagtas, Robin H. SteinhornGreat Ormond Street Hospital for Children. Pfizer Inc. Karolinska Institute and University Hospital. Rady Children’s Hospital and University of California San Diego.United States Journal of PediatricsJ Pediatr 2021; 237: 154-161DOI: 10.1016/j.jpeds.2021.05.051 AbstractObjective: To investigate the efficacy and safety of sildenafil

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial Read More »

Targeted treprostinil delivery inhibits pulmonary arterial remodeling

Aijun Liu, Bin Li, Ming Yang, Yongying Shi, Junwu SuBeijing Anzhen Hospital. The First Affiliated Hospital of Guangzhou Medical University. China European Journal of PharmacologyEur J Pharmacol 2022; 923: DOI: 10.1016/j.ejphar.2021.174700 AbstractIntroduction: Pulmonary arterial hypertension (PAH) is a fatal disease caused by the progressive remodeling of pulmonary arteries (PAs). Treprostinil (TPS) is a tricyclic benzidine prostacyclin clinically

Targeted treprostinil delivery inhibits pulmonary arterial remodeling Read More »

Sildenafil protects against pulmonary hypertension induced by hypoxia in neonatal rats via activation of PPARγ‑mediated downregulation of TRPC

Wanjie Huang, Na Liu, Xin Tong, Yanna DuShengjing Hospital of China Medical University. The First Affiliated Hospital of Zhengzhou University.China International Journal of Molecular MedicineInt J Mol Med 2022; 49: DOI: 10.3892/ijmm.2021.5074 AbstractPersistent pulmonary hypertension of the newborn (PPHN) is a common pulmonary vascular disease during the neonatal period, and it is associated with a high

Sildenafil protects against pulmonary hypertension induced by hypoxia in neonatal rats via activation of PPARγ‑mediated downregulation of TRPC Read More »

Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα

Zongye Cai, Siyu Tian, Theo Klein, Ly Tu, Laurie W. Geenen, Thomas Koudstaal, Annemien E. van den Bosch, Yolanda B. de Rijke, Irwin K. M. Reiss, Eric Boersma, Claude van der Ley, Martijn Van Faassen, Ido Kema, Dirk J. Duncker, Karin A. Boomars, Karin Tran‑Lundmark, Christophe Guignabert, Daphne MerkusErasmus MC University Medical Center. Zhejiang University

Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα Read More »

Vascular Disorders of Pregnancy Increase Susceptibility to Neonatal Pulmonary Hypertension in High-Altitude Populations

Alexandra Heath-Freudenthal, Lilian Toledo-Jaldin, Inge von Alvensleben, Litzi Lazo Vega, Rodrigo Mizutani, Margaret Stalker, Hussna Yasini, Fanny Mendizabal, Jesus Dorado Madera, William Mundo, Melany Castro-Monrroy, Julie A. Houck, Any Moreno-Aramayo, Valquiria Miranda-Garrido, Emily J. Su, Dino A. Giussani, Steven H. Abman, Lorna G. Moore, Colleen G. JulianKardiozentrum. Hospital Materno-Infantil. University of Colorado. Universidad Mayor de San Andrés. University of Cambridge.Bolivia, United States and United Kingdom HypertensionHypertension 2022; 79: 1286-1296DOI: 10.1161/HYPERTENSIONAHA.122.19078 AbstractBackground: Preeclampsia and fetal growth restriction increase cardiopulmonary disease risk for affected offspring and occur

Vascular Disorders of Pregnancy Increase Susceptibility to Neonatal Pulmonary Hypertension in High-Altitude Populations Read More »

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension

Shinichi Takatsuki, Tomotaka Nakayama, Yurika Shimizu, Reiko Kawai, Hiroyuki MatsuuraToho University Omori Medical Center. Kochi Medical School Hospital.Japan Cardiology in the YoungCardiol Young 2023; 33: 196-200DOI: 10.1017/S1047951122000415 AbstractObjective: This study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.Methods: This retrospective cohort study included clinical

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension Read More »

Misclassification of Pulmonary Hypertension in Partial Anomalous Pulmonary Venous Return

Clifford W. Chin, David P. BichellVanderbilt University and Monroe Carell Junior Children’s HospitalUnited States Annals of Thoracic SurgeryAnn Thorac Surg 2022; 114: e447-e449DOI: 10.1016/j.athoracsur.2022.02.021 AbstractPartial anomalous pulmonary venous return is a rare congenital heart defect that can escape detection until adulthood and can be misdiagnosed as pulmonary hypertension and managed with vasodilators before the anomaly is

Misclassification of Pulmonary Hypertension in Partial Anomalous Pulmonary Venous Return Read More »

Prevalence of pulmonary hypertension on echocardiogram in children with severe obstructive sleep apnea

Melissa A. Maloney, Sally L. Davidson, Ramon A. Durazo-Arvizu, Jacqueline M. Breunig, Daniel U. Okpara, Emily S. GillettChildren’s Hospital Los Angeles and University of Southern California Keck School of Medicine.United States Journal of Clinical Sleep MedicineJ Clin Sleep Med 2022; 18: 1629-1637DOI: 10.5664/jcsm.9944 AbstractStudy objectives: Pulmonary hypertension (PH) is a rare yet serious complication of obstructive sleep

Prevalence of pulmonary hypertension on echocardiogram in children with severe obstructive sleep apnea Read More »

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy

Regan E. Geisinger, Amy H. Stanford, Brady Thomas, Steven H. Abman, Patrick J. McNammaraUniversity of Iowa. University of Colorado.United States Journal of PediatricsJ Pediatr 2022; DOI: 10.1016/j.jpeds.2022.11.026 AbstractThe effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10),

Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy Read More »

Scroll to Top